Therapeutic focus Brill Pharma specializes in dermatology and ophthalmology, presenting a targeted opportunity to offer approved innovative therapies and ophthalmic products to hospitals, clinics, and pharmacies within these high-demand areas across Spain and Iberian markets.

Distribution partnerships Existing distribution arrangements for HYLO products in Spain and prior exclusivity deals with Alimera and ILUVIEN suggest a ready-made channel strategy. There is potential to expand co‑marketing or extend distribution to additional ophthalmic and dermatology brands.

Growth potential Brill Pharma envisions introducing high value added products and expanding into other Iberian American markets, signaling opportunities for new product introductions, regional partnerships, and market entry services for sales teams.

Strategic events Active participation in Ophthalmology conferences and hosting dedicated events like the SOFT conference enhances brand visibility and creates direct access to clinicians and purchasing decision-makers for new product opportunities.

Financial and scale context With a revenue range of 10–25 million and a mid‑sized employee base, Brill Pharma presents a scalable partner profile for co‑development, licensing, or distribution agreements with global dermatology and ophthalmology portfolios.